Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer

Federica Di Nicolantonio, Michael H. Neale, Louise A. Knight, Alan Lamont, Geraldine E. Skailes, Richard J. Osborne, Rosanne Allerton, Christian M. Kurbacher, Ian A. Cree

Research output: Contribution to journalArticlepeer-review

Abstract

Liposomal doxorubicin (Caelyx/Doxil) has been shown to be active in around 20% of recurrent ovarian cancers. As yet, there is little clinical data on combinations of existing agents with liposomal doxorubicin, despite considerable clinical experience with soluble doxorubicin in combination. In this study, we have used an ATP-based tumor chemosensitivity assay to determine the relative efficacy of high concentrations of doxorubicin tested in combination with cisplatin, treosulfan, 5-fluorouracil (5-FU) or vinorelbine against cells obtained from recurrent ovarian tumor tissue. The results show little enhancement of the efficacy of high concentrations of doxorubicin by 5-FU, cisplatin, or treosulfan. However, vinorelbine + liposomal doxorubicin showed additive inhibition, and this combination is worthy of further testing in clinical trials.

Original languageEnglish
Pages (from-to)625-630
Number of pages6
JournalAnti-Cancer Drugs
Volume13
Issue number6
DOIs
Publication statusPublished - 2002

Keywords

  • Caelyx
  • Chemotherapy
  • Combination
  • Doxil
  • Liposomal doxorubicin
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Fingerprint

Dive into the research topics of 'Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this